Keywords: Sanofi Pasteur, Sanofi, Vivalis, MAbs, Infectious diseases

Sanofi Pasteur and Vivalis extend MAb accord

Article | 19 January 2012

Print This

French biopharma company Vivalis (NYSE Euronext: VLS) says it has extended the agreement signed in 2010 with Sanofi Pasteur, the vaccines ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in